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Abstract
The 2013–16 Ebola virus disease outbreak in west Africa was associated with unprecedented 
challenges in the provision of care to patients with Ebola virus disease, including absence of pre-
existing isolation and treatment facilities, patients’ reluctance to present for medical care, and 
limitations in the provision of supportive medical care. Case fatality rates in west Africa were 
initially greater than 70%, but decreased with improvements in supportive care. To inform optimal 
care in a future outbreak of Ebola virus disease, we employed the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) methodology to develop evidence-based 
guidelines for the delivery of supportive care to patients admitted to Ebola treatment units. Key 
recommendations include administration of oral and, as necessary, intravenous hydration; 
systematic monitoring of vital signs and volume status; availability of key biochemical testing; 
adequate staffing ratios; and availability of analgesics, including opioids, for pain relief.
Introduction
The 2013–16 Ebola virus disease outbreak in west Africa was associated with 
unprecedented challenges in the provision of care to patients with the disease, including a 
need for acute care that exceeded the number of health workers available, the absence of pre-
existing treatment and isolation facilities, a dearth of treatments specific to Ebola virus, and, 
possibly, limitations in the provision of supportive medical care.1,2
Ebola virus disease is a febrile, multisystem illness, with a predominance of gastrointestinal 
symptoms and signs—namely nausea, vomiting, diarrhoea, and abdominal pain—that 
frequently lead to hypovolaemia, metabolic acidosis, renal dysfunction, and multi-system 
organ dysfunction.1–5
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With initial severe mismatches between care demand and system capacity, and the 
reluctance of people to present for treatment, the initial risk of mortality was greater than 
70%. Individualised clinical supportive care improved as community health and Ebola 
treatment units developed.6 This care included better symptom control, laboratory-facilitated 
diagnosis of organ dysfunction, treatment of shock with enteral and parenteral fluids and 
electrolytes, and rapid diagnosis or empirical treatment of concomitant illnesses such as 
malaria and bacterial infections. Associated with these measures, the case fatality rate 
decreased to approximately 40% throughout west Africa, and declined further while clinical 
and health system experience and capacity increased.6,7
These experiences suggested the need to develop an evidence-based approach to the 
supportive care of patients with Ebola virus disease. Therefore, we developed evidence-
informed guidelines for the delivery of supportive care to patients admitted to Ebola 
treatment units during a future outbreak using the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) methodology.8
Scope and definitions
These guidelines focus on the delivery of supportive care measures to patients in Ebola 
treatment units where health care resources are limited, a context typical in outbreaks of 
Ebola virus disease. The guidelines could be relevant to other infectious diseases with 
clinical syndromes similar to Ebola that are managed in isolation facilities (eg, other 
haemorrhagic fevers). The target audiences include health workers, governmental and non-
governmental health agencies, public health organisations, local and clinical facility 
managers, and health policy makers at all levels.
Group composition and meeting
The multidisciplinary guidelines panel comprised 34 participants: ten critical care physicians 
(two specialists in paediatric care), one critical care nurse, two emergency medicine 
physicians, two general practice physicians, five infectious diseases physicians, one lawyer, 
one psychologist and bioethicist, four public health experts, three health research 
methodologists, one qualitative researcher, one survivor of Ebola virus disease, and three 
WHO staff observers (appendix).
The panel met for two days in London, UK, in August, 2016, and voted on six 
recommendations. The panel finalised two additional recommendations during two follow-
up teleconferences in October, 2016. Voting panellists participated as individuals rather than 
as representatives of the organisations of which they were members.
Formulating questions
The steering committee (FL, RAF, NKA, SM, GHG) used data from a quantitative survey 
and structured interviews of health workers involved in the international response to the west 
African Ebola virus disease outbreak to inform the questions addressed by these guidelines.
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Formulating recommendations
The panel voted on the direction and the strength (strong or conditional) of each 
recommendation. Voting on recommendations was by secret ballot. For a strong 
recommendation, we required 80% of votes in favour, and a smaller proportion in favour of a 
strong recommendation would result in a conditional recommendation. In making 
recommendations, the panel considered the magnitude of benefits and harms,9 the quality of 
supporting evidence, and underlying values and preferences. Following the GRADE 
framework,10 we report our overall confidence in estimates of effect (ie, the quality of 
supporting evidence) using the ratings very low, low, moderate, or high. The confidence in 
effect estimates from randomised controlled trials starts as high, whereas confidence in the 
evidence from observational studies starts as low. Confidence ratings could be decreased if 
there was risk of bias,11 imprecision,12 inconsistency,13 indirectness,14 and likelihood of 
publication bias.15 The rating of observational evidence could be increased in the presence 
of a large magnitude of association, a dose-response gradient, or if all unaccounted 
confounders increase confidence in estimates of effect. The steering committee suggested 
confidence ratings for each evidence summary, and the final assessments were achieved by 
consensus among voting panel members.
Table 1 presents interpretations of strong and conditional recommendations from the 
perspectives of patients, clinicians, and policy makers.8 We restricted strong 
recommendations, when evidence was of low or very low quality, to situations of very high 
mortality in which almost all informed individuals would choose a possibly effective 
intervention, even if evidentiary support is limited.9
Values and preferences
We specified the following value and preference judgments that informed the 
recommendations. We placed a very high value on uncertain, substantial mortality reduction 
associated with any of the interventions and a lower value on very uncertain increase in 
Ebola virus transmission to health-care providers. We placed a much lower value on rare 
complications of antibiotic therapy than on uncertain mortality benefit associated with 
antibiotic administration. We placed a high value on uncertain improvement in psychological 
wellbeing of patients and a lower value on very low and uncertain risk of Ebola virus 
transmission to the family. We placed a very high value on the reduction of pain suffered by 
patients with Ebola virus disease, and a lower value on potential negative perceptions 
associated with the use of specific medications, particularly opioids.
Other considerations
We discussed but did not make recommendations regarding resources, feasibility, and 
equity; recommendations for interventions considered routine in high-income countries; 
diagnosis and treatment of malaria; distinct susceptible populations; the limitations of 
making inferences from data collected in high-resource settings; and the importance of 
continuing clinical research during outbreaks of infectious diseases and, more generally, in 
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low-income and middle-income countries. A description of the group consensus on these 
issues appears in the appendix.
Recommendations
The clinical questions, strength of each recommendation, and confidence in the underlying 
evidence are summarised in table 2.
(1) Oral rehydration
We strongly recommend, with moderate confidence, administering oral rehydration solution 
in an adequate amount rather than non-standardised rehydration
Indirect evidence gathered from other febrile gastrointestinal syndromes with 
relevance to Ebola—ie, cholera—Although the pathophysiology of Ebola virus and 
cholera infections differ, both often result in profuse diarrhoea leading to intravascular 
volume depletion, hypotension, organ hypoperfusion, and, in severe cases, shock. The first 
case series of oral rehydration therapy for cholera reported a reduction in the fatality rate of 
severe cases in a British prison from approximately 50% to 3%.16 In the most severe cases, 
mortality approached 100% without rehydration, but less than 9% of those on oral 
rehydration therapy died.16 In a before and after study of Bangladeshi refugees with cholera 
and cholera-like illness in India in 1971, the case fatality rate decreased from approximately 
30% to 3·6% after the introduction of oral rehydration therapy.17
Human-to-human Ebola virus transmission—Ebola virus is transmitted by direct 
contact with blood or body fluids and possibly through direct skin contact with a person with 
symptomatic Ebola virus disease; airborne transmission has never been conclusively 
reported.18 Ebola virus transmission risk is extremely low with proper infection prevention 
and control (IPC) practices, including appropriate personal protective equipment.18–20 In 
2007, 14 health workers were infected with Ebola virus in Uganda before an isolation ward 
with basic IPC was established, and none afterwards.21 An unrecognised case of Ebola virus 
disease in South Africa had direct contact with over 300 health workers; only one was 
infected with Ebola virus.18,22 Although more than 800 health workers were infected with 
Ebola virus during the 2013–16 west Africa outbreak, most transmissions occurred in 
situations without adequate IPC measures (eg, early in the outbreak, at non-Ebola treatment 
units where patients were not identified as having the disease, when IPC practices were 
infrequently or improperly applied, or in the community).18 Our recommendations apply to 
contexts in which health workers will use appropriate IPC practices and will have contact 
with patients for reasons other than encouraging oral intake. Therefore this intervention will 
not constitute large incremental exposure.
Conclusion and remarks—Oral rehydration therapy probably reduces mortality and is 
unlikely to increase transmission of Ebola virus to health workers. This recommendation 
focuses on ensuring actual fluid intake rather than simply the delivery of an oral rehydration 
solution. Patients who are too young or ill to prepare and drink oral rehydration solution 
independently require active assistance from health-care providers. Adequacy of oral fluid 
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intake refers to the volume that will prevent or correct signs of hypovolaemia and should be 
considered on an individual basis (see third recommendation).
(2) Parenteral administration of fluids
We strongly recommend, with moderate confidence, parenteral administration of fluids 
rather than no parenteral administration for patients who are unable to drink or whose 
volume losses are larger than oral volume intake
Low-income versus high-income countries—Early in the 2013–16 west African 
Ebola virus disease outbreak, systematic administration of intravenous fluids was 
uncommon and 1230 (70·8%) of 1737 patients with Ebola virus disease died,19 compared 
with 5 (18·5%) of 27 patients with the disease who were treated with intravenous fluid 
rehydration in the USA and Europe (relative risk [RR] 0·26, 95% CI 0·12–0·58; risk 
difference [RD] −52.4%, 95% CI −62·3 to −29·7; p<0·0001).23 Care in high-income 
countries included many interventions beyond those we recommend, and their relative 
contribution is uncertain. Nevertheless, parenteral fluids constitute a key component of the 
care that patients in high-income settings received.
Time series of single outbreaks—The Hastings Police Training Centre clinic in 
Freetown, Sierra Leone, reported a decreasing case fatality rate over time from 47·7% 
(n=151) in the first month, to 31·7% (n=126) in the second month, to 23·4% (n=304) in the 
third month24 (first month vs third month RR 0·49, 95% CI 0·38–0·64; RD −24·3%, 95% CI 
−29·7 to −17·3; p<0·0001). Similarly, the case fatality rate across west Africa was greater 
than 70% between January and March, 2014, and decreased to less than 40% between July 
and September, 2015.6,7 This decrease coincided with increased efforts towards improved 
supportive care, including parenteral fluid therapy when necessary. During the 1995 Ebola 
outbreak in Democratic Republic of Congo, 231 (79·1%) of 292 people died before 
intravenous fluids were available, and 14 (56·0%) of 25 people died after fluids were 
introduced (RR 0·71, 95% CI 0·50–1·00; RD −23·1%, 95% CI −39·7 to 0·6; p=0·055).25 
Improved access to parenteral therapy represents one potential explanation for lower case 
fatality rates in these analyses.
Case series of hypovolaemic shock—Intravenous fluid resuscitation was first studied 
clinically during World War 2, and the survival of many soldiers was attributed to the 
administration of colloids and blood transfusions.26 Intravenous crystalloid solution was 
introduced during the Vietnam War and associated to a reduction in case fatality rate from 
hypovolaemic shock.26 However, original reports of the military case series are not readily 
available. On the basis of these initial reports, intravenous fluid resuscitation became 
standard of care for hypovolaemic shock.26 All 140 patients with cholera and hypotension 
survived in a case series of patients treated with intravenous fluid in India in 1965.27
Human-to-human Ebola virus transmission—See evidence summary for the first 
recommendation. Additional use of open-bore needles, which are used during venous 
cannulation to administer parenteral fluids, potentially increases the risk of Ebola virus 
transmission. Although deep needle-stick injuries are probably a high risk for Ebola virus 
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transmission,28 they remain infrequent events when precautions are taken, such as using 
needles with safety features.29
Conclusion and remarks—Parenteral administration of fluids probably reduces 
mortality in patients who are unable to drink or who have inadequate oral intake to keep up 
with current volume losses. Options for parenteral fluid administration include peripheral 
and central intravenous30,31 or intraosseous routes.32 Enteral fluids via nasogastric tube 
could be an acceptable alternative for selected patients (eg, children with difficult 
intravenous access with adequate gastrointestinal motility, mild to moderate volume 
depletion, and tolerance of a nasogastric tube), and with sufficient provider technical skill. 
Results from a three-arm randomised clinical trial comparing albumin fluid boluses, saline 
solution boluses, or no boluses in 3141 children younger than 12 years with severe febrile 
illness and impaired perfusion, showed better survival among patients who were treated 
without fluid boluses.33 We did not consider data from this trial relevant to patients with 
Ebola virus disease because few patients in this trial (<10%) suffered from volume 
depletion, patients with gastroenteritis-like syndromes were excluded, patients in both study 
arms received maintenance intravenous fluids, which we recommend, and because we did 
not address the issue of fluid boluses.
(3) Systematic monitoring and charting of vital signs and volume status
In all patients with Ebola virus disease, we strongly recommend, with low confidence, 
systematically monitoring and charting of vital signs and volume status rather than no 
systematic monitoring or charting.
Hypovolaemia in adults—A systematic review of hypovolaemia in adults identified 
several diagnostically helpful clinical signs.34 A pulse increment of 30 beats per min or 
more, or severe dizziness when standing up from lying down, are highly sensitive (0·97, 
95% CI 0·91–1·0) and specific (0·98, 0·97–0·99) physical findings for severe hypovolaemia, 
defined as acute blood volume loss of more than 600 mL. Supine tachycardia (pulse >100 
beats per min; specificity 0·96, 95% CI 0·88–0·99) and supine hypotension (systolic blood 
pressure <95 mm Hg; specificity 0·97, 0·90–1·0) are helpful to confirm hypovolaemia. Stool 
output can be measured reliably and can guide rehydration requirements: in a case series, all 
41 patients with severe cholera, who received intravenous rehydration in a 1:1 ratio with 
stool output volume, survived.27
Hypovolaemia in children—A systematic review of hypovolaemia in children identified 
helpful clinical signs.35 Prolonged capillary refill was the most reliable predictor of volume 
depletion (likelihood ratio positive test 4·1 [95% CI 1·7–9·8], likelihood ratio negative test 
0·57 [0·39–0·82]). A prospective cohort study36 found that the 12-point DHAKA score, 
combining mental status, respiration, skin pinch, and the presence of tears, might improve 
detection of hypovolaemia (appendix).
Early warning scores in adults—Two cluster-randomised controlled trials have 
examined the effects of medical outreach and early-warning systems. In the first,37 23 
hospitals were randomly assigned to continue functioning as usual or to introduce a medical 
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emergency team system. There was no significant effect on the composite outcome of 
cardiac arrest, unexpected death, or unplanned ICU admission (adjusted odds ratio [OR] for 
composite outcome 0–98, 95% CI 0·83–1·16).37 The second trial38 involved 16 hospital 
wards and found that the introduction of a critical care outreach service reduced in-hospital 
mortality (adjusted OR 0·52, 0·32–0·85).39 A meta-analysis was not possible due to 
heterogeneity.38 A systematic review included four before and after studies of variable 
quality, in the UK and Australia.40 Results from three of these studies suggested that using 
an early warning score improves outcomes.
Early warning scores in children—The Paediatric Early Warning Score was used in a 
case-control study of 2074 children who were evaluated in four hospitals, to identify those at 
risk of cardiac arrest (area under the receiver operating characteristics curve 0·87, 95% CI 
0·85–0·89).41
Human-to-human Ebola virus transmission—See evidence summary for the first 
recommendation.
Conclusion and remarks—Monitoring and documentation of vital signs to detect 
hypovolaemia and early warning signs of poor outcomes might reduce mortality and are 
unlikely to increase transmission of Ebola virus to health workers.
Vital signs are components of the physical examination that can ascertain volume status (ie, 
heart rate, blood pressure, gastrointestinal fluid loss, urine output, and, in children, capillary 
refill, skin pinch, and tears), as well as mental status, respiratory rate, oxygen saturation, and 
temperature. A detailed discussion of specific aspects of the management of fluid depletion 
is beyond the scope of these guidelines. These specific decisions should be made by 
clinicians exercising their clinical judgment after considering, case by case, all context-
specific benefits and risks.42,43 Clinicians seeking such guidance can, however, consult 
several useful sources.44,45
(4) Serum biochemistry
We strongly recommend, with low confidence, that provision for serum biochemistry be 
made available, that testing be done as deemed desirable by the attending clinicians, that 
results be charted, and that interventions in response to the results be implemented according 
to clinicians’ judgment.
Observational study of Ebola virus disease—In a cohort study46 of 150 patients with 
Ebola virus disease in Sierra Leone, serum potassium and acid-base disturbances were 
associated with increased risk of death. Three (4%) of 69 survivors and ten (36%) of 28 non-
survivors had a potassium measurement greater than 5·1 mmol/L (p<0·001 after adjusting 
for severe acute kidney injury). In patients with Ebola virus disease, low total carbon dioxide 
(7 [39%] of 18), hyponatraemia (36 [32%] of 113), hypokalaemia (19 [20%] of 97), and 
hyperkalaemia (13 [13%] of 97) were common in patients with Ebola virus disease;46 all are 
independent predictors of mortality.47–51 Although all of these factors are surrogate markers 
for risk of death—mostly from cardiac arrhythmias or brain oedema—reversal of electrolyte 
derangements might mitigate the risk.
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Low-income versus high-income countries—See evidence summary for the second 
recommendation. In the USA and Europe, clinical management systematically included 
close monitoring and correction of biochemical abnormalities.23
Human-to-human Ebola virus transmission—Blood sampling, transport, and 
laboratory testing carries some risk of Ebola virus transmission. As mentioned previously, 
the absolute risk of transmission is small and can be mitigated by proper IPC practices and 
equipment, including needles with safety features. Moreover, virological testing for Ebola 
diagnosis already requires blood sampling from infected patients. Therefore, the 
measurement of serum electrolytes is possibly associated with a small incremental risk of 
Ebola virus transmission.
Conclusion and remarks—Measuring and charting serum biochemistry with a clinically 
relevant correction of abnormalities might reduce mortality. This intervention could result in 
a small increase in the risk for Ebola virus transmission to health workers. Whenever 
possible, biochemistry tests should be consolidated with Ebola virus testing and with blood 
sampled via an existing intravenous line or needles with safety features to minimise the risk 
of needle-stick injury. In addition to the expected survival benefits associated with treatment 
of severe biochemical abnormalities, the intervention could reduce iatrogenic deaths caused 
by inappropriate administration of electrolytes (eg, potassium in acute renal failure),46 and 
brain oedema associated with rapid correction of hypernatraemia with hypotonic solutions.
(5) Staffing ratio
We strongly recommend, with moderate confidence, an Ebola treatment unit staffing ratio of 
at least one clinician to four patients, including the following considerations—patient 
assessment at least 3 times per day and continuous (24 h per day) monitoring of patients to 
allow prompt recognition of and reaction to acute changes in condition.
Observational data in high-income countries—A meta-analysis52 of five 
observational studies found that an increase by one nurse full-time equivalent per patient-day 
was associated with a reduced risk of death in intensive care units (OR 0·91, 95% CI 0·86–
0·96). There was a clear dose-response relationship.
Low-income versus high-income countries—See evidence summary for the second 
recommendation. In the USA and Europe, patients were treated in units with a nurse:patient 
ratio of 1:1 or more and had continuous monitoring.23
Human-to-human Ebola virus transmission—See evidence summary for the first 
recommendation. Increasing the clinician-to-patient ratio probably increases the contact time 
between health workers and patients. However, increased clinician:patient ratios could also 
prevent fatigue, especially when working in full personal protective equipment for extended 
periods, thereby preventing IPC mistakes. However, no published data has addressed this 
issue.
Conclusion and remarks—Increased clinician-to-patient ratios probably reduce 
mortality. The direction of effect, if any, on the risk of Ebola virus transmission is unknown. 
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The term clinician encompasses nurses, clinical officers, and physicians. In practice, 
clinicians work with a partner or team in the isolation zone to ensure adherence to 
appropriate IPC practices. The minimum recommended clinician:patient ratio is an average 
(eg, could vary within Ebola treatment units on the basis of clinical severity). The clinical 
contact time likely influences care more than staffing ratios per se. Monitoring of patients 
can be facilitated by Ebola treatment unit design and technology.53 Non-clinician health 
workers can support clinical staff (eg, to assist in administration of oral rehydration 
solution).
(6) Communication with family and friends
We conditionally suggest, with low confidence, facilitating communication with family and 
friends for patients admitted to the treatment unit with suspect, probable, or confirmed Ebola 
virus disease
Psychological distress—Results from four studies showed that patients admitted to 
hospital who were isolated had higher depression and anxiety scores than those who were 
not isolated, whereas one study did not.54 Other effects on psychological wellbeing included 
anger or hostility, fear, and lone liness.54 In west Africa, community distress about unknown 
activities in Ebola treatment units generated resistance, on occasions ranging from denying 
health-care workers access to communities to violent opposition to the Ebola response.55
Human-to-human Ebola virus transmission: Risk of Ebola virus transmission to visitors 
is zero under strict isolation. The risk is probably extremely low if contact is allowed across 
a sufficient distance or a barrier to prevent droplet spread.
Conclusion and remarks—Facilitating the communication of isolated patients with 
family and friends, including enabling the use of cell phones or the internet, might reduce 
psychological distress and can be achieved without increasing the risk of Ebola virus 
transmission. Closer contact situations, including burials,56 can be safe if appropriate IPC 
practices, such as use of physical barriers, are employed.
(7) Analgesic therapy
We strongly recommend, with high confidence, the use of analgesic therapy, including 
parenteral opioids, if necessary to reduce pain.
Pain—Analgesic medications are beneficial for acute pain in almost all scenarios. For 
example, all opioid analgesics tested in a network meta-analysis of randomised trials 
improved pain scores, compared with placebo.57 A review58 of morphine for post-surgical 
analgesia found a large, immediate, and dose-dependent effect on pain after administration 
compared with placebo.
Adverse effects—Analgesic medications may be associated with adverse effects, some of 
them serious, but evidence of the magnitude of risk applicable to the clinical management of 
patients admitted to Ebola treatment units is unavailable. This recommendation assumes that 
the risk of serious adverse effects can be minimised through good clinical practice.
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Human-to-human Ebola virus transmission—See evidence summary for the second 
recommendation.
Conclusion and remarks—Analgesic therapy reduces pain. With the available evidence, 
it was not possible to assess whether nonsteroidal anti-inflammatory analgesics (particularly 
those that inhibit cyclooxygenase-1) should be avoided because of anti-platelet effects or 
risks of acute kidney injury in the setting of Ebola virus disease. Satisfactory implementation 
of this recommendation will probably require the education of local health workers, family 
members, and communities to address negative views of opioids.59
(8) Antibiotics
We strongly recommend, with moderate confidence, prompt administration of broad-
spectrum antibiotics to patients with suspect, probable, or confirmed Ebola virus disease and 
high severity of illness.
Mortality—Multiple time series and randomised clinical trials done between 1930 and 
1950 consistently show that antimicrobials reduce mortality associated with bacterial 
infections.60,61
Antibiotic-related complications—In a multicentre prospective cohort study of 4143 
patients, the overall incidence of healthcare-associated Clostridium difficile infection was 
28·1 cases per 10 000 patient-days.62 The OR of C difficile infection for antibiotics was 5·25 
(95% CI 2·2–12·8). In a retrospective cohort study of 34 298 adult inpatients in a large 
acute-care teaching hospital, the overall incidence of C difficile infection was 5·95 per 10 
000 patient-days.63 Each 10% increase in ward-level antibiotic exposure (measured in days 
of antibiotic therapy per 100 patient-days) was associated with a 2·1 per 10 000 (p<0·001) 
increased incidence in C difficile. In a longitudinal cohort study of 110 656 adults aged 66 
years or older who resided in nursing homes, the risk of allergic reactions to antibiotics 
varied from 0% in homes with low antibiotic exposure to 0·1% in homes with high antibiotic 
exposure.64
Antibiotic resistance—Antibiotic use can increase antibiotic resistance. However, the 
degree of antibiotic use we recommend for the management of patients during an Ebola 
virus disease outbreak probably represents a negligible increase in the overall use of 
antibiotics, and it is therefore unlikely to have a significant effect on antibiotic resistance.
Human-to-human Ebola virus transmission—See evidence summary for 
recommendation 2.
Conclusion and remarks—Prompt administration of antibiotics probably reduces 
mortality among patients with bacterial infections. Antibiotic administration might result in 
a small increase in antibiotic-related complications and risk of Ebola virus transmission to 
health workers. Patients with suspect, probable, or confirmed Ebola virus disease and high 
severity of illness might be ill because of Ebola virus infection, bacterial infection, malaria, 
other infectious illnesses, or a combination of these infections. WHO provides guidance for 
the investigation and management of malaria.65 This eighth recommendation addresses the 
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possibility of bacterial infection as a primary or concurrent cause of illness when micro-
biology laboratory infrastructure is insufficient. The rationale is that when ruling out 
bacterial infections is not possible, the consequence of not treating undiagnosed bacterial 
infections would probably lead to serious incremental morbidity and mortality.66 In 
situations when micro biological analyses are available, consideration should be given to 
obtaining cultures (eg, blood, urine, or respiratory, as relevant) before initiating antibiotics if 
this can be achieved without delaying therapy. This approach would plausibly reduce the 
duration of initiated broad-spectrum antibiotics, considering that bacterial co-infection might 
affect a minority of patients.67 In all cases, patients should be reassessed 48 h after initiation 
of treatment to determine whether antibiotics are still necessary (on the basis of clinical 
condition and culture results, if available). In adults, clinicians can infer high severity of 
illness from early warning scores discussed for recommendation. In African patients 
younger than 15 years who are admitted to hospital for a febrile illness, the prevalence of 
bacteraemia is high and therefore we recommend prompt use of antibiotics, regardless of 
illness severity.68 Critically ill patients will generally receive intravenous antibiotics, but 
clinicians could choose to administer oral antibiotics after considering bioavailability and 
likelihood of absorption (ie, if there is no vomiting).
Conclusion
First-hand accounts of the care that was delivered during the 2013–16 west African outbreak 
of Ebola virus disease provided impetus for these guidelines, which address interventions 
that are otherwise considered routine.69
Indirectness considerably limits the quality of the evidence that informed these 
recommendations. One of the reasons for this dearth of evidence is that during the past 40 
years, after 18 outbreaks and more than 30 000 reported cases of Ebola virus disease, 
clinical descriptions were mostly limited to the presenting signs and symptoms for a very 
small proportion of all cases (ie, this was an unrepresentative sample).23 Applying these 
recommendations could not only improve outcomes but enable data collection that will 
inform future practice.
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Search strategy and selection criteria
We searched MEDLINE, MEDLINE In-Process, Embase, Cochrane Database of 
Systematic Reviews, Cochrane Central, African Index Medicus, and PubMed for papers 
published in any language between the first available date in each database and February, 
2016. For our systematic scoping review of interventions for shock and shock-like 
syndromes in resource-limited settings, we included an extensive list of illnesses that 
share characteristics with Ebola virus disease (Ebola, shock, cholera, sepsis, and other 
severe diarrhoeal illnesses) and we did not limit the search to specific interventions. 
Additional data to populate the evidence summaries was acquired by a more targeted 
search of PreMEDLINE and grey literature (eg, medical history textbooks, literature that 
is not controlled by commercial publishers). The complete systematic scoping review 
appears in the appendix.
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